American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
 Accreditation of IHMA Europe, Enhancing Support for Clinical Trials in Anti-Infective Drug Development and Global Surveillance Studies - EconoTimes)
SCHAUMBURG, Ill., March 06, 2018 -- On 14th October 2017 IHMA Europe Sàrl, located in Monthey, Valais, Switzerland, was awarded accreditation by the College of American Pathologists (CAP). With this important development both IHMA facilities, located in the US and Europe, are now CAP accredited. These accreditations further advance IHMA’s global commitment to the highest quality of central laboratory clinical microbiology services that are essential for providing timely and accurate results in support of anti-infective clinical trials and global surveillance studies on a worldwide basis.
IHMA Europe's Chief Executive Officer, Dr Stephen Hawser said, “CAP accreditation is a truly positive acknowledgement of the high quality of services IHMA Europe provides to the pharmaceutical and biotechnology industries to support antimicrobial development".
Jack Johnson, President and CEO of IHMA said, “It has been our desire to globalize the two laboratories to ensure our pharmaceutical and biotechnology clients, that all services provided by IHMA and IHMA Europe are exactly the same and meet the highest standards and quality found in our industry. The CAP accreditation provides that platform.”
About IHMA, Inc. and IHMA Europe Sàrl
IHMA is based in Schaumburg, IL USA and Monthey, Switzerland and has been a premier provider of antimicrobial drug development services over the past 25 years. Our laboratory facilities in both the US and Europe partner with clients around the world in the biotechnology, pharmaceutical, and diagnostic industries. IHMA is a leading, independent laboratory specializing in surveillance studies and clinical trials, key milestones along the continuum from drug development to commercialization. IHMA utilizes state of the art technology, leading to first-class testing and data as well as sound economic frameworks. IHMA’s services can be customized to best align with its clients’ unique testing needs. This ensures successful drug development, commercialization, and post-marketing pathways.
For more information, visit the IHMA website at: www.ihma.com
CONTACT INFORMATION
Igael Hamburg
Marketing Director
[email protected]
